Theophylline

Theophylline

Clinical data
Pregnancy category	AU: A US: C (Risk not ruled out)
Routes of administration	oral, IV
ATC code	R03DA04 (WHO)
Legal status
Legal status	UK: P (Pharmacy medicines)
Pharmacokinetic data
Bioavailability	100%
Protein binding	40%, primarily to albumin
Metabolism	hepatic to 1-methyluric acid
Elimination half-life	5-8 hours
Identifiers
IUPAC name 1,3-dimethyl-7H-purine-2,6-dione
CAS Number	58-55-9
PubChem CID	2153
DrugBank	APRD00082
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C7H8N4O2
Molar mass	180.164 g/mol
3D model (JSmol)	Interactive image
SMILES CN1C(=O)N(C)c2nc[nH]c2C1=O

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Theophylline, also known as dimethylxanthine, is a methylxanthine drug used in therapy for respiratory diseases such as COPD or asthma under a variety of brand names. Due to its numerous side-effects, these drugs are now rarely administered for clinical use. As a member of the xanthine family, it bears structural and pharmacological similarity to caffeine. It is naturally found in tea, although in trace quantities (~1 mg/L), significantly less than therapeutic doses.

The main actions of theophylline involve:

• relaxing bronchial smooth muscle
• increasing heart muscle contractility and efficiency: positive inotropic
• increasing heart rate: positive chronotropic
• increasing blood pressure
• increasing renal blood flow
• some anti-inflammatory effects
• central nervous system stimulatory effect mainly on the medullary respiratory center.

History

Theophylline was first extracted from tea leaves around 1888 by the German biologist Albrecht Kossel. The drug was chemically identified in 1896, and eventually it was synthesized by another German scientist, Wilhelm Traube. Theophylline's first clinical use in asthma treatment came in the 1950s.

Pharmacokinetics

Absorption

Bioavailability is 100%. However, taking the drug late in the evening may slow the absorption process, without affecting the bioavailability. Taking the drug after a meal high in fat content will also slow down the absorption process, without affecting the bioavailability. There is one exception. Taking Uniphyl^TM, a long-acting theophylline formulation, after a meal high in fat content will increase its bioavailability.

Distribution

Theophylline is distributed in the extracellular fluid, in the placenta, in the mother's milk and in the central nervous system. The volume of distribution is 0,5 L/kg. The protein binding is 40%. The volume of distribution may increase in neonates and those suffering from cirrhosis or malnutrition, whereas the volume of distribution may decrease in those suffering from obesity.

Metabolism

Theophylline is metabolized extensively in the liver (up to 90%). It undergoes N-demethylation via cytochrome P450 1A2. It is metabolized by parallel first order and Michaelis-Menton pathways. Metabolism may become saturated (non-linear), even within the therapeutic range. Small dose increases may result in disproportionately large increases in serum concentration. Methylation in caffeine is also important in the infant population. Smokers and people with hepatic (liver) impairment metabolize it differently.

Elimination

Theophylline is excreted unchanged in the urine (up to 10%). Clearance of the drug is increased in these conditions: children 1 to 12, teenagers 12 to 16, adult smokers, elderly smokers, kystic fibrosis, hyperthyroidism. Clearance of the drug is decreased in these conditions: elderly, acute congestive heart failure, cirrhosis, hypothyroidism and febrile viral illness.

The elimination half-life varies: 30 hours for premature neonates, 24 hours for neonates, 3.5 hours for children ages 1 to 9, 8 hours for adult non-smokers, 5 hours for adult smokers, 24 hours for those with hepatic impairment, 12 hours for those with congestive heart failure NYHA class I-II, 24 hours for those with congestive heart failure NYHA class III-IV, 12 hours for the elderly.

Indications

The main therapeutic uses of theophylline are aimed at:

• chronic obstructive diseases of the airways
• chronic obstructive pulmonary disease (COPD)
• bronchial asthma
• infant apnea.
• Central apnea with congestive heart failure

Mechanisms of action

The main mechanism of action of theophylline is that of adenosine receptor antagonism. Theophylline is a non-specific adenosine antagonist, antagonizing A1, A2, and A3 receptors almost equally, which explains many of its cardiac effects and some of its anti-asthmatic effects.

Another proposed mechanism of action includes a non-specific inhibition of phosphodiesterase enzymes, producing an increase in intracellular cyclic AMP; however, this is not known with certainty.

Theophylline has been shown to inhibit TGF-beta-mediated conversion of pulmonary fibroblasts into myofibroblasts in COPD and asthma via cAMP-PKA pathway and suppresses COL1 mRNA, which codes for the protein collagen.

It has been shown that theophylline may reverse the clinical observations of steroid insensitivity in patients with COPD and asthmatics that are active smokers (a condition resulting in oxidative stress) via a distinctly separate mechanism. Theophylline in vitro can restore the reduced HDAC (histone deacetylase) activity that is induced by oxidative stress (i.e., in smokers), returning steroid responsiveness toward normal. Furthermore, theophylline has been shown to directly activate HDAC2. (Corticosteroids switch off the inflammatory response by blocking the expression of inflammatory mediators through deacetylation of histones, an effect mediated via histone deacetylase-2 (HDAC2). Once deacetylated, DNA is rewound around histones and repackaged so that the promoter regions of inflammatory genes are unavailable for binding of transcription factors such as NFB that act to turn on inflammatory activity. It has recently been shown that the oxidative stress associated with cigarette smoke can inhibit the activity of HDAC2, thereby blocking the anti-inflammatory effects of corticosteroids.) Thus theophylline could prove to be a novel form of adjunct therapy in improving the clinical response to steroids in smoking asthmatics.

Through the adenosine inhibition, theophylline may treat central apnea in the setting of severe congestive heart failure. However, theophylline may also cause an increase in renin which may cause a decrease in ace inhibiotion effect.

Side-effects

The use of theophylline is complicated by the fact that it interacts with various drugs, chiefly cimetidine and phenytoin, and that it has a narrow therapeutic index, so its use must be monitored to avoid toxicity. It can also cause nausea, diarrhea, increase in heart rate, arrhythmias, and CNS excitation. Its toxicity is increased by erythromycin, cimetidine, and fluoroquinolones. It can reach toxic levels when taken with fatty meals, an effect called dose dumping.

Synthesis

Theophylline can be prepared synthetically starting from dimethylurea and ethyl 2-cyanoacetate.

•